Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment: 2010-2024

Historic Asset Writedowns and Impairment for Ani Pharmaceuticals (ANIP) over the last 8 years, with Dec 2024 value amounting to $7.6 million.

  • Ani Pharmaceuticals' Asset Writedowns and Impairment was N/A to $7.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $10.3 million, marking a year-over-year change of. This contributed to the annual value of $7.6 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Asset Writedowns and Impairment is $7.6 million, which was up 1,224.04% from $574,000 recorded in FY2022.
  • Over the past 5 years, Ani Pharmaceuticals' Asset Writedowns and Impairment peaked at $7.6 million during FY2024, and registered a low of $445,000 during FY2020.
  • In the last 2 years, Ani Pharmaceuticals' Asset Writedowns and Impairment had a median value of $4.1 million in 2022 and averaged $4.1 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first spiked by 493.33% in 2020, then slumped by 75.82% in 2022.
  • Ani Pharmaceuticals' Asset Writedowns and Impairment (Yearly) stood at $445,000 in 2020, then skyrocketed by 433.48% to $2.4 million in 2021, then crashed by 75.82% to $574,000 in 2022, then reached $7.6 million in 2024.